bioequivalence of drug combination [Regulatives / Guidelines]

posted by balakotu – India, 2018-04-13 06:40 (1292 d 23:39 ago) – Posting: # 18675
Views: 1,395

(edited by Ohlbe on 2018-04-13 10:22)

Hello Norah,
As per USFDA, it is mandatory to perform separate studies for separate products.
FDA will not accept plain candesartan ANDA without BE studies.
Moreover, candesartan a BCS class II product and waiver approach (based on combination product BE study) is not possible to get the waiver for plain Candesartan.


Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post! [Ohlbe]

Complete thread:

Activity
 Admin contact
21,758 posts in 4,550 threads, 1,544 registered users;
online 4 (0 registered, 4 guests [including 3 identified bots]).
Forum time: Wednesday 06:19 CEST (Europe/Vienna)

There ain’t no rules around here!
We’re trying to accomplish something!    Thomas Alva Edison

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5